About Phillips Medisize
Phillips Medisize is a Healthcare company based in Chippenham (United Kingdom) founded in 1997, and was acquired by Phillips Medisize in May 2025. Inhaled therapeutics for respiratory diseases are developed. It operates on a Professional Services and Reseller / Distribution model. Phillips Medisize has raised $15.21 million across 2 funding rounds from investors including Boehringer Ingelheim, Molex and Philip Morris International. Phillips Medisize has completed 3 acquisitions, including Activaero, Skyepharma and Syqe. Its chief executive, as recorded, is Will Downie. Phillips Medisize offers products and services including Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector. Its focus areas include Medical Devices and Inhalation Therapy Devices. Its legal entity is Phillips Medisize – a Molex Company.
Company details
Phillips Medisize, incorporating Vecturas expertise since 2025, is focused on inhaled drug development. Services are offered in formulation science, device technology, and development for inhalation therapies. Solutions are provided for small molecules, biologics, and complex combinations across pMDI, DPI, nasal inhalers, and nebulizers. Contributions have been made to 13 launched inhaled medicines, benefiting millions globally. Sectors served include pharmaceutical and medtech industries with a focus on respiratory health solutions.
- Headquarters Chippenham, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website vectura.com
- Social LinkedIn X Facebook YouTube
- Acquired by Phillips Medisize (May 2025)
- Legal Name Phillips Medisize – A Molex Company
- Total Equity Funding$15.21M (USD)
in 2 rounds
- Latest Funding Round$21.76M (USD), Post-IPO
Nov 2007
- InvestorsBoehringer Ingelheim
& 4 more
- Investments & AcquisitionsActivaero
& 2 more
- Acquired by
Products & Services of Phillips Medisize
Phillips Medisize offers a comprehensive portfolio of products and services, including Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector.
Devices for delivering dry powder inhalation therapies effectively.
Inhalers providing metered doses for respiratory treatment solutions.
Nebulizer using vibrating mesh for efficient drug delivery.
Smart autoinjector designed for precise drug administration ease.
Apps and channels of Phillips Medisize
its YouTube channel Phillips Medisize, a Molex company has 273 subscribers and 30 videos.
Videos from Phillips Medisize
The most watched videos on Phillips Medisize's YouTube channel, Phillips Medisize, a Molex company (273 subscribers). Click a video to play it here.
More on Phillips Medisize, a Molex company.
Funding Insights of Phillips Medisize
Phillips Medisize has successfully raised a total of $15.21M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.76 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.21M
- Total Rounds 2
- Last Round Post-IPO — $21.76M
- First Round $15.21M
(Apr 2001)
- Investors Count 2
All 2 funding rounds of Phillips Medisize with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2007 | $21.76M | Post-IPO | – | – | |
| Apr 2001 | $15.21M | Series B | – | – |
5 investors in total: 5 institutional.
Investors in Phillips Medisize
Phillips Medisize has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Boehringer Ingelheim, Molex and Philip Morris International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are managed across the UK. | 1984 | nvm.co.uk | Newcastle Upon Tyne, United Kingdom | |
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com | ||
Communication equipment manufacturer | 1938 | molex.com | Lisle, United States | |
Multi-category tobacco products, including cigarettes and heated options, are manufactured. | 1847 | pmi.com | Neuchatel, Switzerland | |
Medical device product design and development services are offered. | 1964 | phillipsmedisize.com | Hudson, United States |
Investor details for Phillips Medisize
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Phillips Medisize
38 people are tracked at Phillips Medisize (7 in leadership, 31 in team).
| Name | Role | Group |
|---|---|---|
Will Downie | CEO | Leadership |
Richard Poole | Director - Centre Of Excellence (inhaled Product Solutions) | Leadership |
Gonzalo De Miquel | Chief Medical Officer & EVP, Development | Leadership |
Andrew Whiston | VP - EHS & Facilities | Leadership |
Charis Lawrence | Head Of Business Systems | Leadership |
Mark Harris | Head Of Tax And Treasury | Leadership |
Anabela Goncalves | Director Of Quality | Leadership |
Matthew Pollard | SVP, Commercial Operations | Team |
Maria Oliveira | Senior Human Factors Engineer | Team |
Olivia Tomkins | Senior Scientist | Team |
Samantha Kellett | Senior Finance Manager - UK Controlling | Team |
Geraldine Venthoye | EVP, Pharmaceutical Development | Team |
John Murphy | General Counsel & Company Secretary | Team |
Antony Fitzpatrick | EVP, Operations | Team |
Bas Hoffmann | Inside Sales Manager | Team |
Richard Emerson-Pink | Senior Facilities Manager | Team |
Kirsty Fitch | Supply Chain Lead | Team |
George Hall | Supply Chain Lead | Team |
Andrew Wilcox | Supply Chain Lead | Team |
Craig Fulton | Senior Scientist | Team |
18 more people are available in the full profile.
Complete people profiles for Phillips Medisize
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Phillips Medisize
Phillips Medisize has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Activaero, Skyepharma and Syqe.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Precise dosing inhaler for medical cannabis is developed. | syqe.com | Tel Aviv, Israel | 2011 | Jul 2023 | •••• | |
Developer of small molecule based oral and inhalation products for the treatment of various diseases | skyepharma.com | London, United Kingdom | 1996 | Mar 2016 | $621M | |
Controlled breathing technologies for inhaler devices were developed. | activaero.de | Gemunden, Germany | 2004 | Mar 2014 | $181M |
Complete acquisition details for Phillips Medisize
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Phillips Medisize
10 dated milestones of Phillips Medisize across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Phillips Medisize is founded.
- Funding First funding round of $15.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $21.8M.
- Acquisition Acquires Activaero.
- Acquisition Acquires Skyepharma.
- Exit Acquired by Philip Morris International.
- Acquisition Acquires Syqe.
- Exit Acquired by Molex.
- Exit Acquired by Phillips Medisize.
Web traffic of Phillips Medisize
Websites that share an audience with Phillips Medisize (vectura.com).
- Global rank#13,827,917
among all websites
- Category rank#8,494
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.2
- DevicesDesktop 13% · Mobile 87%
Websites whose visitors overlap most with Phillips Medisize. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hikma.com | 100% | 159K | #227,704 | View details | |
| vernacare.com | 70% | 14.1K | #1,938,882 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phillips Medisize
Complete news archive for Phillips Medisize
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phillips Medisize
Phillips Medisize was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Phillips Medisize is headquartered in Chippenham, United Kingdom.
Will Downie is the CEO of Phillips Medisize, as recorded in our data.
Phillips Medisize is a funded company, having raised a total of $15.21M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15.21M, raised on Apr 2001.
Phillips Medisize, incorporating Vecturas expertise since 2025, is focused on inhaled drug development. Services are offered in formulation science, device technology, and development for inhalation therapies. Solutions are provided for small molecules, biologics, and complex combinations across pMDI, DPI, nasal inhalers, and nebulizers. Contributions have been made to 13 launched inhaled medicines, benefiting millions globally. Sectors served include pharmaceutical and medtech industries with a focus on respiratory health solutions.
Phillips Medisize offers Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector.
Phillips Medisize has made 3 acquisitions, including Activaero, Skyepharma, and Syqe.
Phillips Medisize has 5 investors. Key investors include Boehringer Ingelheim, Molex, Philip Morris International, NVM Private Equity, and Phillips Medisize.
Phillips Medisize operates through Phillips Medisize – A Molex Company.
Yes. Phillips Medisize was acquired by Phillips Medisize in May 2025.